Fibrosis markers in hepatitis C

Current Hepatitis Reports

Volumn 5, Issue 3, 2006, Pages 86-93

  Brady, Carla W ^b   McHutchison, John G ^b   Patel, Keyur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALGORITHM; CHRONIC HEPATITIS; CLINICAL PRACTICE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; ELASTOGRAPHY; ENZYME DEGRADATION; ENZYME SYNTHESIS; FIBROSIS; GOLD STANDARD; HEALTH CARE COST; HEPATITIS C; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; REVIEW; RISK FACTOR;

EID: 33750364761     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-006-0010-3     Document Type: Review

References (34)

1. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999, 31(Suppl 1):3-8.
2. Afdhal NH: The natural history of hepatitis C [review]. Semin Liver Dis 2004, 24(Suppl 2):3-8.
3. Regev A, Berho M, Jeffers LJ, et al.: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
4. Intraobserver with interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
5. Bedossa P, Dargère P, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
6. Guechot J, Laudat A, Loria A, et al.: Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42:558-563.
7. Leroy V, Monier F, Bottari S, et al.: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271-279.
8. Abe S, Narita R, Hiura M, et al.: Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C. J Gastroenterol 2004, 39:247-254.
9. Walsh KM, Timms P, Campbell S, et al.: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999, 44:624-630.
10. Murawaki Y, Yamada S, Ikuta Y et al.: Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999, 30:1090-1098.
11. Boeker KHW, Haberkorn CI, Michels D, et al.: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002, 316:71-81.
12. Wong VS, Hughes V, Trull A, et al.: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepatitis 1998, 5:187-192.
13. McHutchison JG, Blatt LM, De Medina M, et al.: Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000, 15:945-951.
14. Körner T, Kropf J, Gressner AM: Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996, 25:684-688.
15. Patel K, Lajoie A, Heaton S, et al.: Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003, 18:253-257.
16. Johansen JS, Christoffersen P, Moller S, et al.: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920.
17. Patel K, Rockey DC: Clinical utility of biomarkers of liver fibrosis. Gastroenterol Hepatol 2006, 1:48-57.
18. Kanzler S, Baumann M, Schirmacher P, et al.: Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β. J Viral Hepat 2001, 8:430-437.
19. Forns X, Ampurdanès S, Llovet JM, et al.: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
20. Wai C, Greenson JK, Fontana RJ, et al.: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
21. Fix OK: The performance of APRI for the diagnosis of significant hepatic fibrosis is improved by a simple modification. Paper presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; November 11-15, 2005, Abstract 597.
22. Sud A, Hui JM, Farrell GC, et al.: Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004, 39:1239-1247.
23. Imbert-Bismut F, Ratziu V, Pieroni L, et al.; MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
24. Poynard T, Imbert-Bismut F, Munteanu M, et al.: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8-19. This comprehensive overview incorporates a meta-analysis of published studies on the diagnostic utility of the FibroTest-ActiTest (FT-AT) and new statistical analyses that assess the impact of hepatitis C virus genotype and viral load on the performance of FT-AT and compare the performance of FT-AT with other serum fibrosis markers.
25. Poynard T, Munteanu M, Imbert-Bismut F, et al.: Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355.
26. Patel K, Gordon SC, Jacobson I, et al.: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935-942. This study tested and validated the three-marker panel, FIBROSpect II®, which is commercially available in the United States.
27. Rosenberg WM, Voelker M, Thiel R, et al.; European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
28. Ziol M, Handra-Luca A, Kettaneh A, et al.: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
29. Castera L, Vergniol J, Foucher J, et al.: Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
30. Callewaert N, Van Vlierberghe H, Van Hecke A, et al.: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429-434.
31. Mora R: Diagnostic value of biochemical markers, FibroTest-ActiTest-HCV- FibroSure (FT-AT) compared with serum protein profiling by SELDI-TOF protein chip (STP), for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; October 29-November 2, 2005, Abstract 810.
32. Sebastiani G, Vario A, Guido M, et al.: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006, 44:686-693.
33. Adams LA, Bulsara M, Rossi E, et al.: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873.
34. Calés P, Oberti F, Michalak S, et al.: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.